NeuVasQ is based on new insights into the molecular mechanisms maintaining the integrity of the blood-brain barrier (BBB). The BBB regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in many neurological conditions through the leakage of harmful blood substances into the CNS. BBB dysfunction is a factor in many neurodegenerative disorders, such as Alzheimer’s, Parkinson’s and ALS, as well as stroke, epilepsy, and brain tumors. By precisely targeting the pathways responsible for BBB integrity, NeuVasQ has been able to restore lost functionality to the neurovasculature. This unique and targeted approach has the potential to safely improve patient lives in a wide range of neurological disorders. Currently in a preclinical discovery phase, NeuVasQ is focusing on a range of neurological and neurodegenerative disorders. The company is also examining various innovative therapeutic modalities, including small molecule, protein, gene and mRNA therapy.